Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine, Oxaliplatin and Radiation Therapy in Pancreatic Cancer
NCT00242190Phase 2Completed
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jun 2004
- Primary completion
- Mar 2006
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in pancreatic cancer (PC), sponsored by University of Michigan Rogel Cancer Center. Primary endpoint: Dose Limiting Toxicity. Started Jun 2004; status: completed.
02
Drugs
oxaliplatin
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00242190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242190.